Thyroid cancer remains the highest prevailing endocrine malignancy, and its incidence rate has progressively increased in the previous years. Above 95% of thyroid tumor are follicular cells types of carcinoma in which are considered invasive type of tumor. The pathogenesis and molecular mechanism of thyroid tumors are yet remains elucidated, in spite of activating RET, RAS and BRAF carcinogenesis have been well introduced. Nemours molecular alterations have been defined and have revealed promise for their diagnostic, prognostic and therapeutic capacity but still need further confirmation. Among different types of mechanisms, the current article reviews the importance of epigenetic modifications in thyroid cancer. Increasing data from previous reports demonstrate that acquired epigenetic abnormalities together with genetic changes plays an important role in alteration of gene expression patterns. Aberrant DNA methylation has been well known in the CpG regions and profile of microRNAs (mi-RNAs) expression also involved in cancer development. In addition, the gene expression through epigenetic control contribution to thyroid cancer is analyzed and it is semi considered in the clinic. However the epigenetic of the thyroid cancer is yet remains in its early stages, and it carries encouraging potential thyroid cancer detections in its early stages, assessment of prognosis and targeted cancer treatment.

甲状腺癌仍是最高的内分泌恶性肿瘤，其发病率在过去几年中逐渐增加。甲状腺肿瘤的95％以上是滤泡细胞类型的癌，其中被认为是浸润性肿瘤。尽管激活了RET，RAS和BRAF致癌作用，但仍未阐明甲状腺肿瘤的发病机理和分子机制。Nemours分子改变已被定义，并已显示出其诊断，预后和治疗能力的希望，但仍需进一步证实。在不同类型的机制中，当前文章回顾了表观遗传修饰在甲状腺癌中的重要性。以前报告中越来越多的数据表明，获得性表观遗传异常以及遗传变化在基因表达模式的改变中起着重要作用。DNA甲基化异常在CpG区域众所周知，microRNA（mi-RNA）表达谱也与癌症发展有关。此外，分析了通过表观遗传控制对甲状腺癌的贡献的基因表达，并在临床中被半考虑。然而，甲状腺癌的表观遗传学仍处于早期阶段，并且在早期阶段具有令人鼓舞的潜在甲状腺癌检测，预后评估和靶向癌症治疗的潜力。DNA甲基化异常在CpG区域众所周知，microRNA（mi-RNA）表达谱也与癌症发展有关。另外，分析了通过表观遗传控制对甲状腺癌的贡献的基因表达，并在临床上被半考虑。然而，甲状腺癌的表观遗传学仍处于早期阶段，并且在早期阶段具有令人鼓舞的潜在甲状腺癌检测，预后评估和靶向癌症治疗的潜力。DNA甲基化异常在CpG区域众所周知，microRNA（mi-RNA）表达谱也与癌症发展有关。另外，分析了通过表观遗传控制对甲状腺癌的贡献的基因表达，并在临床上被半考虑。然而，甲状腺癌的表观遗传学仍处于早期阶段，并且在早期阶段具有令人鼓舞的潜在甲状腺癌检测，预后评估和靶向癌症治疗的潜力。